

**Supplemental Table 1.** Bias risk assessment of the studies

Study name	Random sequence generation	Allocation concealment	Blind participants and personnel	Blind outcome assessment	Incomplete outcome data	Selective reporting
APEX-MI	Low risk	Low risk	Low risk	Low risk	Low risk	<i>Unclear</i> risk
COMPLY	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
COMMA	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Pexelizumab Study	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Investigators PRIMO	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
CABG I	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
PRIMO CABG II	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
MRC-ILA Heart	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
VCU-ART I&II	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
VCU-ART3	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
COLCOT	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
LoDoCo	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
STABILITY	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
SOLID	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
TIMI-52	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
FRANCIS	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
VISTA-16	Low risk	Low risk	Low risk	Low risk	<i>High</i> risk	Low risk
CANTOS	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
SELECT-CABG	Low risk	Low risk	Low risk	Low risk	<i>High</i> risk	<i>Unclear</i> risk
LATITUDE MI-60	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
SOLSTICE	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk